ArticleBiotechnology and bioengineering2022
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.
Article in Biotechnology and bioengineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial.The Lancet. Infectious diseases · 2026Trial
- Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.EBioMedicine · 2022Trial
- DNA-based vaccines: Advances, applications, and future prospects.Genes & diseases · 2026Review
- Editorial: The WHO Identifies Ebola Disease Due to Bundibugyo Virus as a Public Health Emergency of International Concern (PHEIC) as Vaccine Development Accelerates.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Multi-omics reveal molecular changes during suspension adaptation of HEK293 cells.Applied microbiology and biotechnology · 2026Article
- An Efficient TetR/TetO-Integrated Packaging System for Fowl Adenovirus 4 Vector Carrying Toxic Transgene.Methods and protocols · 2026Article
- Critical Path to First-in-Human Batches of ChAdOx Vectors, Including for Emergency Response.Vaccines · 2026Article
- Developing the next-generation of adenoviral vector vaccines.Human vaccines & immunotherapeutics · 2025Review
- Streamlined purification of ADDomer nanoparticles for scalable biomanufacturing.Journal of biological engineering · 2025Article
- Integrating Affinity Chromatography in the Platform Process for Adenovirus Purification.Biotechnology and bioengineering · 2025Article
- Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.Vaccine · 2025Article
- COVID-19 vaccination in patients with multiple sclerosis: what you need to know - a review.Health science reports · 2024Article
- Optimization of Culture Media and Feeding Strategy for High Titer Production of an Adenoviral Vector in HEK 293 Fed-Batch Culture.Vaccines · 2024Article
- Trends in COVID-19 Vaccine Development: Vaccine Platform, Developer, and Nationality.Vaccines · 2024Article
- Development of Adenovirus-Based Covid-19 Vaccine Candidate in Indonesia.Molecular biotechnology · 2024Article
- Contrasting academic approaches to COVID-19 vaccine production and distribution: What can the Oxford and Texas experiences teach us about pandemic response?Health affairs scholar · 2024Article
- Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response.Biotechnology and bioengineering · 2024Article
- Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster.Human vaccines & immunotherapeutics · 2023Article
- Article
- Humoral immunity to phlebovirus infection.Annals of the New York Academy of Sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
Manufacturing has been the key factor limiting rollout of vaccination during the COVID-19 pandemic, requiring rapid development and large-scale implementation of novel manufacturing technologies. ChAdOx1 nCoV-19 (AZD1222, Vaxzevria) is an efficacious vaccine against SARS-CoV-2, based upon an adenovirus vector. We describe the development of a process for the production of this vaccine and others based upon the same platform, including novel features to facilitate very large-scale production. We discuss the process economics and the "distributed manufacturing" approach we have taken to provide the vaccine at globally-relevant scale and with international security of supply. Together, these approaches have enabled the largest viral vector manufacturing campaign to date, providing a substantial proportion of global COVID-19 vaccine supply at low cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.